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Fig. j. Advanced trachoma
showing bilateral ptosis and cor-
neal opacity of and discharge
from the left eye.
For a present-day understanding of trachoma, the historical
background, with the implied and reported high incidence,
the deficiencies and triumphs of the centuries of empirical
investigations before the aetiological agent was known,
and the clarification afforded by recent discoveries by
medical science, will need to be briefly discussed. Also,
as trachoma is a chronic infection, comparison with the
behaviour of other chronic infections, particularly tuber-
culosis, is illuminating. Finally, as it is much the com-
monest ocular infection in Natal' and in the rest of South
Africa'" in all racial and social groups, trachoma (or if
preferred, TRIC agent infection) merits attention as an
uncomplicated ocular infection and as a very common
complicating factor in all external ocular diseases and in
eye surgery.
HISTORICAL BACKGROUND AND INCIDENCE
Newton Kugelmass' states that man and many of his
maladies have not changed appreciably in the last 20,000
years. Trachoma embraces nearly 5 millennia, being known
in China in the 27th century BC. It was endemic in the
20th and 19th century BC in Egypt and was common in
Greece in the 5th century BC. Celsus described trachoma
in AD 14 and a Sicilian, Pedanius Dioscorides,' named
it for its rough feel in AD 60. Amida described its 4
stages in AD 550 (also delineated by Galen' circa AD
160). The Ebers papyrus of Thebes, dating from 1500 BC,
of which a translation was pUblished in 1875: men-
tions infections in which the eyes become inflamed, de-
velop granulations and inturned eyelashes, and become
purulent.' Thygeson' mentions the exudative and cicatri-
cial features, and its treatment with copper salts. If it can
be assumed that these reports of trachoma in the impor-
tant centres of the ancient world are true, and considering
the lack of knowledge of hygiene and treatment until
recent times, the accessibility of the discharges and the
long duration of infec-
tivity, it would be not
difficult to prove that
all, or nearly all, of the
rest of the human race
were infected long ago.
No country or conti-
nent can be expected to
be free of it.
It is not surprising
that the clinical picture
most commonly evoked
is of its most severe
form, represented by a
bedraggled, dirty indi-
vidual with red, dis-
charging eyes, inturned
eyelashes and opaque
corneae, with flies all
over the face. He is
usually partially or Wholly blind (Fig. 1). The picture
described is certainly true of severe trachoma where igno-
rance, deprivation and neglect have allowed it to reach this
terrible state, but it ignores the much more common, mild
form and its various manifestations in people of all races
and stations in life.
Inaccuracies still Occur in recent literature, such as
'trachoma does not affect the eyes of Negroes',' or 'the
aetiological agent, a member of the psittacosis-lympho-
granuloma venereum group, that invades the epithelium of
the conjunctiva and cornea and no other human structure'.'
In contrast it is pleasant to applaud the clinical acumen
which allowed Galen to delineate 4 stages. Also admired is
the percipience of Fordor' who, in 1927, considered the
epidemic conjunctival affection occurring in large cities as
a subacute form of the disease which, when it occurs
acutely, is called 'inclusion-body blennorrhoea of the new-
born' and, when chronic, 'trachoma'.
Fordor's views do not appear to have had much in-
fluence, with the result that 1,800 years after Galen, his
4 stages amplified by MacCallan8 and the World Health
Organization of the United Nations remained the stan-
dard clinical assessment.
The inclusion bodies which they named chlamydozoa
(mantle bodies) were found by Halberstaedter and Von
Prowazek'o in Java in 1907, at first in experimental tra-
choma in apes and later in human trachoma. Before 1911
identical inclusioil bodies had been found in bacteria-free
ophthalmia neonatorum,n in female genital epithelium"
and non-gonococcal urethritis." The disease had been re-
produced in the eyes of a monkey and a baboon from
genital secretion from a mother whose baby had inclusion
blennorrhoea. and inclusion bodies were recovered from
the conjunctiva of the baboon."
Lindner" had identified his initial bodies as early as
1910, and the complex nature, and variation in site, of
trachoma infection had been indicated.
After initial successes by Macchiavello" In 1944 and
Stewart and Badir" in 1950, Tang et al."'1O isolated strains
of virus from trachoma cases in serial yolk-sac culture,
produced follicular conjunctivitis in 7 rhesus monkeys,
and recovered typical HP inclusions from one of them.
They demonstrated susceptibility to penicillin, tetracycline
and chloramphenicol, and insusceptibility to streptomycin,
and indicated a toxic factor associated with the elemen-
tary bodies. In 1958, Collier and Sowa'" and Collier
et al." produced trachoma in the eye of a human volun-
teer from a strain of trachoma agent isolated in Gambia.
This strain had had 8 passages in ovo. They also demon-
strated complement-fixing antibodies and the presence of
a common complement-fixing antigen for the psittacosis-
lymphogranuloma venereum group of viruses.
Since then, the virus has been isolated in egg culture
from thousands of cases in this country alone. Human
conjunctivae have been infected with egg cultures of
trachoma virus, with production of papillary hypertrophy,
follicles and pannus by Scott et al."-'" and in similar ex-
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periments in other countries."'" Trachoma in a modified
form has been produced in the orang-utan,'· the chim-
panzee," baboons"'''''' and some monkeys, ".38.30 although
most laboratory animals are not affected." Complement
fixation,'" dark field agglutination and immunofluore-
scent..·., antibodies have been identified, and serological
protection against trachoma has been demonstrated in
vaccine experiments."'.",3:1
A SUGGESTED PRESENT-DAY DESCRIPTION OF TRACHOMA
As stated in Part n, I consider it timely to define tra-
choma simply as an infection by the TRIC agent." Defi-
nition based on only some of the clinical effects is in-
complete and misleading, just as consumption is not a
Fig, 2. Inclusion bodies from conjunctival smears stained
by Giemsa's stain (oil immersion x 1,000). The smaller
dots are elementary bodies and stain red with Giemsa.
The larger dots (initial bodies) stain blue. Photographs are
by Mr. C. R. Stuart and the preparation by Prof. K. C.
Watson of University of Natal Medical School.
complete definition of tuberculosis. As trachoma is a
chronic infection, it should have similaritie with other
chronic infections, and 1 think that comparative description
with, for example, tuberculosi , may serve as an illu tra·
tion.
The essential lesion of tuberculosis is the pre ence of
tubercle bacilli in the tissues, classically, but by no means
always, those of the lung. In response to the presence of
the tubercle bacilli and their toxin, there is a host reac-
tion involving Iymphocytes and endothelioid and giant cells
which comprise the essential tubercle. In addition, there is
scar-tissue reaction, to repair or attempt to contain the
tubercles. Local necrosis and caseation, and more wide-
spread reactions of delayed hypersensitivity occur. From
these elements the great variety of sites and severity of
the tuberculosis disease is derived.
In comparison, I see the essential lesion of trachoma as
being the presence of virus inclusion bodies in a cell,
classically, but by no means always, a conjunctival epi-
thelial cell (Fig. 2). In response to the presence of the
trachoma virus and its toxins, there is a host reaction in-
volving lymphocytes, plasma cells and polymorphs which.
with epithelial overgrowth, completes the essential lesion
of trachoma (Fig. 3). In addition, there is scar-tissue re-
action, to repair or attempt to contain the essential
lesion; but this is usually 2-dimensional, as the classical
site of infection is epithelial (Fig. 4). Local necrosis,
usually in the form of ulceration (Fig. 5), and reactions of
delayed hypersensitivity occur.
When the biological balance between host and virus i
altered to favour the invader, a subacute or even an acute
form of the disease occurs. Should a more even biological
balance return, the more chronic, and le s severe, state of
the disease is resumed. It becomes contained, or may be
eliminated completely.
After an initial infection, a variable degree of hyper-
sensitivity and of immunity is usual in tuberculo is and to
Fig. 3 Fig. 4 Fig. 5
Fig. 3. An inflamed meibomian cyst, from the conjunctival surface of which TRIC virus was cu1ture~. The re.t of the con-
junctiva at the canthi, fornices and upper tarsus was not cong~ted, but showed signs of long~standlr:tg I~actl~e trachoma.
The local inflammation, activated by the associated pathology, IS a good example of the congestIOn, .epnh~hal thlcke!1lOg and
papillary hypertrophy comprising the basic lesion of trachom<l;' Fig. 4. Sht;els and bands of 2-dlmenslO~al scam.ng. Tra-
choma III in a Bantu child. Fig. 5. Corneal ulcer aSSOCiated wnh trachoma 10 a woman aged 80 years, glVlOg a hi tory of
a sore eye for 50 years. The darker areas to the right of the high . light on the upper tarsal plate represent a trachoma
follicle 3 mm. in diameter which overlies the ulcer when the eye IS closed.
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Fig. 6. The 6th day of acute trachomatous infection in a woman aged 34
years, showing chemosis and congestion. This was accompanied by an
enlarged and tender pre-auriCUlar lymph gland, reduced corneal sensation,
mucous discharge from the eye, upper respiratory symptoms and mild pyrexia.
Fig. 7. An II-year-old child with a history of trachoma for 6 years. This
indicates the potential, though fortunately unusual, seriousness of trachoma
even in White patients.
Fig. 8. Quiet trachoma showing vessels running horizontally on the upper
tarsal plate and discrete small follicle remnants. TRIC virus was cultured
from the conjunctiva of her husband and son-in-law but not from this patient
herself. Fig. 9. Symblepharon. Two bands in the outer half of the lower
fornix can be seen extending from the bulbar conjunctiva to the lower lid
edge. Symptoms date from World War I in Egypt. There were old pannus
encroaching onto the pupil and reduction of corrected visual acuity to 6/12,
and entropion and trichiasis.
Fig. 7
Fig. 9
and viral-particle and protein absorption and to breaches
in the epithelial barrier against the external environment.
Increasing numbers of Iymphocytes, plasma cells and poly-
morphs gather in the submucosa and in the papillae.
Larger clusters may be visible as discrete white, grey or
yellow hemispheres, often in or rising above the papillary
hypertrophy, on the tarsal plates and in the fornices. These
Fig. 6
Fig. 8
a lesser and variable degree in tra-
choma...·..·.. Renna" has reported that
trachoma antibodies in human milk
decrease after the 5th day. These may
protect the infant and may explain the
rarity of neonatal ocular infection in
heavily infecteq countries such as
Egypt, as observed by Thygeson" and
Maxwell-Lyons.53 The finding of in-
direct and fluorescent antibodies to
trachoma elementary bodies in con-
junctival fluid, sometimes in higher
concentration than in the serum,"'"
suggests that immunity is a local as
well as a humoral phenomenon.
The initial infection may find such
effective resistance that it is contained
or eliminated with a minimal reaction
by the host. In tuberculosis, there may
be only a very small scar in a lung,
and a slightly enlarged and fibrosed
related lymph gland. In trachoma, the
tissue change may be limited to non-
congested papillae, usually along the
edge of the upper tarsal plate, which
may be visible only with the slit-lamp
microscope, and of which the patient
is usually unaware. In other cases, the
initial infection may find weak de-
fences or be especially virulent, so
that in tuberculosis, pyrexia, cough
and considerable damage in the lung
might follow. In similar circumstances
in trachoma, there may be gross swell-
ing and congestion of the conjunc-
tivae, mucous and mucopurulent dis-
charge, enlargement of the related pre-
auricular lymph gland, pyrexia and
upper respiratory symptoms (Fig. 6).
This acute type of reaction has been
seen in several adult patients in my
practice, usually in visitors to the
country and recent immigrants. It
might be due to lack of resistance to
local virus strains, as enhanced sensi-
tivity to heterologous strains has been
reported:""'" If such virulent infec-
tion is not controlled, the result might
be death in tuberculosis or blindness
in trachoma, after a few months or
years (Fig. 7).
CLINICAL PICTURE
There is an increase in mitosis of the
conjunctival epithelium in order to
replace lost cells. and the epithelium thickens to 5 or 6
layers instead of 2 or 3 on the tarsal plates. Subconjunctival
blood-vessels are seen less distinctly through the thickened
epithelium. The epithelium also increases in breadth, so
that it is raised into minute papillae (papillary hyper-
trophy). Blood supply in the submucosa is increased to
meet the raised metabolic demands, in response to toxic
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Fig.10(a) Fig. lO(b)
Fig. 10. Keratinized socket of a man aged 83 years. All conjunctival secretion
had ceased. The remaining eye had pannus, massive scarring, symblepharon,
entropion and trichiasis. A prosthesis had been worn in the sock~t until a
severe illness 7 years earlier. Symptoms dated from World War I In Egypt.
may be seen only with the slit-lamp microscope or may be
up to 2 - 3 mm. in diameter and may become confluent
(Fig. 7). These I regard as trachomatous follicles. They
resemble minute lymph nodes. The related pre-auricular
lymph gland may be involved, with enlargement and
tenderness, which may persist for months. To maintain
this exuberant inflammation, new blood-vessels grow in
horizontally from the ends of the upper tarsal plates and
after cure remain as evidence of previous trachoma (Fig.
8). On the cornea there might be multiple superficial
erosions or larger ulcers (Fig. 5).
Where the infection has persisted for long enough,
and in the case of reinfection, delayed hypersensitivity
may be added to a variable degree. The mechanism or
mechanisms for the production of pannus may be, or may
include, hypersensitivity. This has been suggested by the
production of pannus in monkeys and in humans following
sensitization by vaccine or by reinfection."'''''',,, In some
cases I have found severe pannus associated with mild
conjunctival trachoma. In these and in some severe con-
junctival cases, good and sometimes striking response to
intensive local corticosteroid therapy, always combined
with anti trachoma treatment, has suggested that hypersensi-
tivity was an important factor in the pathology.
Where a chronic granulomatous inflammation has been
severe enough and of sufficient duration, there is an
envelopment and replacement by scar tissue (Fig. 4). This
is seen first with the slit-lamp microscope as stellate or
arachnoid patterns, usually in the conjunctiva of the lower
tarsal plate, and along the upper edge and outer ends of
the upper tarsal plates. In time, if the disease continues,
the threads of scar tissue thicken and may resemble bas-
ket work, and then coalesce to form irregular sheets and
bands. Where the inflammatory reaction has affected
deeper tissues, there is contracture of the submucosa with
bands of symblepharon and ectropion or entropion
(Fig. 9). Contracture on the tarsal-plate surface of upper
and lower lids leads to retraction of the line of the ostia
of the meibomian glands and erosion of the lid edge
(Figs. 3, 5 and 8). The upper tarsal plate may be bent con-
vexly forward, along the subtarsal groove, and this, with
absorption of the tissues of the tarsal plates,
increases entropion and may lead to trichia-
sis. The irritation of inturned eyelashes
usually causes infection to flare up, and there
is danger of corneal damage and opacity.
Corneal sensation is enhanced or reduced at
any stage, and may be abolished. The me-
chanism might be a neurotoxin or incarcera-
tion of the nerves in the inflammation,
especially at and near the limbus. The lacri-
mal ducts may be obstructed by scar tissue,
and goblet cells and mucin-secreting glands
may be destroyed in the inflammation, so
that reduction or abolition of secretions
(Fig. 10) is added to the picture which now
includes most of the horrible ocular features
of classical descriptions, ancient and
modern.
Clinical Course
The course of trachoma, like that of
tuberculosis, is affected by local, general and
environmental factors which alter the resist-
ance of the patient and community."
Just as tuberculosis is not necessarily confined to the
lungs, infection by the TRIC agent is not necessarily con-
fined to the conjunctival sac. In 1956 Poletf'" transmitted
trachoma to the lip, with formation of follicles and inclu-
sion bodies, and in recent years TR IC agent ha been
isolated in ova from the cervix,""'" urethra,"·"" rec-
tum,""" nose,"" throat,""'« tonsils,' middle ear," joints,""'"
ulcers in the mouth:' and the anterior chamber.·'
Strains of TRIC agent vary in their tendency to affect
tissues other than the eye"·.. ·TO and in the frequency with
which severe ocular disease is produced.n Mann" ha
suggested that strain differences may explain in part the
differing clinical pictures found in isolated communities
in Australia and neighbouring islands. In my experience,
patients who have lived in the Middle East appear to have
classical scarring of the upper tarsal plates more often
than patients in South Africa, and Scon' has commented
on the rarity of Arit's line in his White patients.
While these observations may be attributed to differences
in the trachoma agent, variations in the environment and
other factors may be as or more important.
DIAG OSIS OF OCULAR TRACHOMA
In examination eversion of the eyelids is essential, and
use of magnification, preferably the slit-lamp microscope,
is necessary if all the minutiae are to be disclosed.
A high proportion of successful cultures is achieved. A
dry throat-swab should be moistened with streptomycin
solution and applied to the everted upper tar al plates, being
gently revolved. It is not necessary to use force, as it is
mainly the epithelium that is infected, and affected cell
are easily caught in the cottonwool. A drop of local
anaesthetic such as Novesine 0·4% or Xylocaine 2°{, is
helpful. The end of the wooden stick, including the swab,
is broken into a small rubber, screw-capped, bijou bottle
containing 1 - 2 ml. of sterile water or saline containing
10 mg. of streptomycin/ml. The bottle should be posted
by airmail to the SAIMR Trachoma Unit. p.a. Box
1038, Johannesburg, or any other laboratory able to
culture the virus. I have had successful cultures from
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specimens which have been 4 days in transit, but the re-
sults are best if they arrive within 24 hours. After the
trauma from collection of the swab, gentle as the pro-
cedure has been, a flare-up of the infection, occasionally
severe, might occur. It is advisable to commence treat-
ment immediately to anticipate this possibility.
Syncope
A note of caution about possible syncope from a sen-
sitive ocular-vagal reflex is advisable. This has occurred
in some degree in about lout of 500 - 1,000 of my
patients, and it can be alarming. The faintness is often
felt after 5 - 15 minutes, sometimes some minutes after
the examination has been completed. Sudden vomiting
may occur. There is usually a quick improvement on
loosening the collar and tie and bending the head be-
tween the knees, and this is sometimes all that is required.
In other cases the improvement is followed by another wave
of faintness, with marked bradycardia, and there may be
unconsciousness for several minutes. Patients should not
be allowed to leave for at least 20 minutes after recovery
from a mild attack, in view of the possibility of a second
more severe reaction. Injection of atropine might be help-
ful, but fortunately this has not as yet been necessary
in my cases. It is as well to complete the examination of
the everted lids quickly, as the mechanism is probably
traction on the levator muscles during this part of the
investigation. These attacks of faintness have not occurred




In my experience, at least 3 - 6 months of intensive topi-
cal treatment and perhaps a month of systemic sulphona-
mide therapy is usually the minimum required to achieve
clinical cure of trachoma.
Treatment of infected relatives is necessary, to prevent
reinfection of a severely afflicted patient. Scmetimes treat-
ment of mild trachoma is indicated for its aggravating
effect on associated pathologies as discussed in Part Ill.59
Patients with mild trachoma are likely to suffer severely
from their own horrifying mental picture of trachoma,
and strong reassurance to anticipate and to counter mental
distress is part of the treatment.
Problems of Prolonged Topical Therapy
It is important that the highest tolerable concentration
of drugs in the conjunctival sac for many of the 24 hours
of the day be achieved if their limited efficacy is to be
exploited fully. Aqueous drops are usually well tolerated;
but their concentration in the conjunctival sac is effective
for very few minutes, so that application 10 - 20 times a
day is desirable. Effectiveness may be prolonged by ad-
juvants such as methyl cellulose or polyvinol alcohol,
allowing less frequent dosage. An equivalent eye ointment
prolongs the effect during sleep. Irritating eyedrops lose
some of their efficacy as increased tear secretion hastens
their dilution, so that a 10% solution of sulphacetamide
may be more effective than one of 30%. Addition of a
vasoconstrictor such as adrenaline to sulphacetamide eye-
drops may be helpful. Reduction of congestion is soothing,
and the cosmetic effect encourages frequent dosage. It is
possible that removal of sulphacetamide from the extra-
cellular fluid of the submucosa may be retarded by the
vasoconstrictor. These possible advantages are reduced if
the adrenaline causes increased irritation.
Eye ointments are tolerated badly by many patients,
but are preferred to eyedrops by a few, especially small
children. They are convenient for use in mass treatments.
The base may do harm to conjunctival epithelial cells and
thus weaken their defence against the TRIC agent. This
could explain why some patients in clinical trials para-
doxically become worse after treatment with eye oint-
ment.'" Vision is blurred by ointment, but the prolonged
effect is useful during hours of sleep. During waking
hours the amount applied should be very small. Patients
whose tear secretion is reduced find eye ointments parti-
cularly irritating, and aqueous drops are preferred by them.
Systemic Trearment
The growing list of non-ocular TRIC infection men-
tioned earlier, suggests that topical treatment of the
conjunctiva may not be enough. I prefer to use the same
drug topically and systemically. Some authors favour
oral sulphonamide combined with topical antibiotic eye
ointment."
With the new long-acting sulphonamides Kelfizine
(Farmitalia):K,75''; and Fanasil (Roche),"·81 usually given
as weekly doses for 2 - 4 months, the good results reported
have been ascribed to persistence of therapeutic levels
and a high proportion of 'free' sulphonamide which
allowed low dosages. Jawetz et al." found that volun-
teers receiving 1:% tetracycline eye ointment for 2 - 3
weeks remained fluorescent-antibody positive, while most
of those on sulfisoxazole 1 G I.i.d. became negative on the
first day. The danger of a Stevens-Johnson syndrome
must be borne in mind.83 ,..
CORTlCOSTEROlDS AND HYPERSENSITIVITY
That topical corticosteroids may aggravate or activate
conjunctival infections by the TRIC agent has been re-
ported since 1952,',85.91 so that this form of treatment
should be used with care. That hypersensitivity plays an
important part in the pathology is also widely re-
ported,33,,,.,,, so that treatment to counter this aspect
should theoretically be useful. In my experience" local
corticosteroids have proved invaluable in cases where hy-
persensitivity to the TRIC agent or to other allergens
appears to dominate the clinical picture, and in some
cases with excessive corneal involvement. Sulphonamide or
appropriate antibiotic treatment should be continued
while the local corticosteroid is used. Corticosteroid eye-
drops 10 - 15 times a day should be tried on one eye at
first. The patient should be examined after 5 days, when
adverse effects, if they occur, should be apparent. If its
effect is obviously beneficial, the treatment should be
extended to the other eye. When no further improvement
has occurred, the frequency of dosage of corticosteroid
eyedrops should be reduced to the minimum required to
maintain the improvement, but the antimicrobial treat-
ment should be maintained at full dosage until clinical
cure is achieved.
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Other risks associated with topical corticosteroids in
the conjunctiva are possible activation of herpes simplex
virus infection with potentially disastrous effect on the
cornea, and possible induction of glaucoma, especially in
elderly patients. It is to be stressed that while local
corticosteroids are valuable in treatment of selected cases,
they should be used with care.
Influe/'lce of Aggravating Facwrs
Warren" has stressed the adverse effect of secondary
bacterial infection on trachomatous eyes. This has also
been mentioned by others."""'" On the other hand,
Crotty et al."'" found a small blindness-rate in Australian
aboriginals who had a remarkably low incidence of
pathogenic bacteria in the eyes and nose; and Eiselen
and Gear'"' in the Caprivi Strip of South West Africa
found few cases of blindness, entropion, trichiasis and
other complications, while very few cases showed infec-
tion with Kock-Weeks bacilli or pneumococci. Sedan'o,
considers superinfection an important complication with-
out which trachoma is a quiet disease as is seen in Japan
where trachoma is without secondary infection.
Dust has been shown by various workers to have an
important bearing on the production of entropion and
trichiasis.n .,..,'" Mann" found the disease in Australia and
the islands to the north to be worse when use of textiles
and poor hygiene coexisted. Good general standards of
hygiene are essential.
MEDICATIONS AVAILABLE
Of the more commonly used drugs the sulphonamides,
erythromycin, the tetracyclines and the penicillins appear
to be most effective against trachoma. Chloramphenicol
is not as effective experimentally, but is favoured by
some authorities, especially in Russia.""" HursCoc reported
a synthetic compound ICI 17025 (Nitractin) as having an
action comparable with that of the best of the antibiotics in
OVO, but it has two disadvantages in that secondary
bacterial infection is not affected and it has to be
administered parenterally. Strains of trachoma agent
varied in their susceptibilities to tetracycline and different
penicillins1O'l and sulphonamides,'" so that in practice a
trial-and-error selection of the best medications may be
required.
Drug Resistance Acquired by Trachoma Agents
Resistance to sulphonamides by the trachoma agent in
ovo was reported by 10hnston et aI.,"" and Wemer" has
reported a strain which became sulphamethoxypyrazine-
dependent. He found that sulphonamide-resistant strains
tended to replicate more slowly than others in egg culture,
but increased proportionately in the presence of sulphona-
mide. When the sulphonamide was withdrawn, the pro·
portion of non-resistant strains increased. For this reason
I usually limit courses of treatment with sulphonamide to
6 - 8 weeks and interpose a similar course of the tetra-
cyclines or erythromycin between courses of sulphona-
mide, although patients who have used sulphacetamide
eyedrops continuously for several months have often
done well.
Considering how common trachomatous infections have
been found to be and how often sulphonamides and anti-
biotics are used in private practice for all orts of ocular
and non-ocular indications, there mu t be innumerable
strains of trachoma agent which have urvived expo ure
to these drugs and which might be better fitted to urvive
further exposures, including those intended as trachoma
treatment. Against this argument Schiao et al.'os found
no difference in drug sensitivities between trains isolated
in 1958 - 1960 and those isolated in 1963 - 1964, so that
poor responses to antibiotic therapy could not be explained
by development of resistance between these period 10
terms of their experiment. Tarrizzo"° could not develop
strains resistant to erythromycin in at least 10 pa ages in
eggs with increasing amount of erythromycin.
Trachoma Vaccines
These are still largely experimental and none ha yet
achieved general acceptance. llI Bietti eT al.'" found benefit
for up to 3 years, and Scott,'" using live vaccine, found
some protection for up to a year. Proliferation in the
skin, lymph nodes and spleen of baboons'" and
guinea-pigslH after injection of live TRIC agent suggests
a danger from use of live vaccines.
RESULTS OF TREATME T OF TRACHOMA I NATAL
AND ZULULAND
The first course of treatment has usually been sulphace-
tamide 10 - 15% eyedrops with or without methyl cellu-
lose, polyvinol alcohol or adrenaline ): 4,000, 8 - 20 time
a day for 6 - 8 weeks. Where required, this has been re-
inforced by oral long-acting sulphonamide for up to 30
days, subject to the approval of the patient's general
practitioner. After this a tetracycline eye-ointment q.i.d.
for 6 - 8 weeks has been given, followed,. if necessary,
by another 6 - 8 weeks of sulphacetamide or sulfiso-
xazole eyedrops. Clinical cure is often evident before this
routine has ended. Where warranted by the severity, the
oral sulphonamide may be repeated with the eyedrop.
If the infection is still active, further courses of sulphona-
mides, tetracycline and erythromycin are given in turn.
Courses of penicillin eyedrops 25,000 units/ml. and eye
ointment 80,000 units/G for 2 - 3 weeks and perhaps oral
penicillins have been helpful. In particularly severe cases
oral tetracyclines or erythromycin have been given.
Local corticosteroids have usually been withheld until
the infection has been reduced by one or more courses
of antimicrobial therapy, or unless there has been no
significant improvement. However, where the clinical ap-
pearance resembled that of vernal catarrh, and so ug-
gested a considerable allergic component, as noted by
Guerra and Vozza,ll5 topical corticosteroids have been ap·
plied with benefit after only a week or two of antimicro-
bial therapy,
In some cases initial improvement has been followed by
stalemate for months and years. In despair, treatment ha
sometimes been abandoned, but invariably the disease has
become more active, indicating. as the Red Queen told
Ajice, that one has to run as fast as one can to tay in
one place. In order to progress, it has been necessary to
enlist most or all of the therapies discussed above. In every
case, fortunately, persistence has been rewarded.
Table I refers only to 182 White patients from who e
conjunctivae TRIC agent has been isolated in egg culture
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TABLE I. RESULTS OF TREATMENT OF 182 WHITE PATIENTS FIlOM WHOM TRIC AGENT WAS ISOLATED IN EGG CULTURE
Receiving Receiving Reinfected or
Duration of local Severity grade Total systemic local Clinically UncI/red relapsed after
treatment treatment corticosteroid cured clinical cure
No. % No. % No. % No. % No. %
3-6 months 1 36 7 19·4 0 0 29 80·6 7 19·4 5 17'2
2 81 28 34·6 2 2·5 65 80·2 16 19·8 12 18'4
3 27 14 51·9 3 1·1 22 81·5 5 18·4 5 22·8
4 5 3 60·0 0 0 5 100·0 0 0 1 20·0
5 2 1 50'0 0 0 2 100·0 0 0 0 0
3-6 months 1-5 151 53 36·1 5 3·3 123 81· 5 28 19·5 23 19·5
6-12 months 1 2 I 50·0 0 0 I 50·0 I 50·0 1 100·0
2 9 2 22·2 0 0 6 66·7 3 33·3 3 50'0
3 5 3 60·0 0 0 4 80·0 I 20·0 I 25·0
4 3 2 66·7 0 0 2 66·7 I 33·3 1 50·0
5 3 2 66'7 1 33·3 3 100·0 0 0 2 66·7
6-12 months 1-5 22 10 45·5 1 4·5 16 72·7 6 27·3 8 50'0
1-3 years 1 0 0 0 0 0 0 0 0 0 0 0
2 1 I 100'0 0 0 I 100·0 0 0 0 0
3 4 3 75·0 2 50·0 3 75·0 J 25·0 2 66·7
4 2 2 100·0 I 50·0 2 100·0 0 0 I 50·0
5 2 I 50·0 2 100·0 0 0 2 100·0 0 0
Total 1-3 years 1-5 9 7 77·8 5 55·6 6 66'7 3 33·3 3 50·0
0-3 years 1-5 182 70 38'5 II 6·0 145 79·7 37 20·3 34 23·4
Systemic treatment 1-5 70 70 100·0 8 11·4 55 78·6 15 21·4 12 21·8
Corticosteroids 1-5 II 8 72·7 II 100·0 8 72·7 3 27·3 3 27·3
Local treatment alone 1-5 112 0 0 3 2·7 90 80·4 22 19·6 22 23·3
and whose treatment was completed at least 6 months
before the time of w.riting.
Assessment of clinical cure was usually made a month
after treatment was stopped. It was arbitrarily based on
the significant decline in, or disappearance of, signs of
papillary hypertrophy, follicles, pannus, or conjunctival
scarring and absence of inflammation. Subjective improve-
ment was not considered, though it usually preceded and
exceeded the improvement in physical signs. The relapses
or reinfections were mild or asymptomatic. Those severe
enough to warrant further treatment usually responded
well. Treatment was administered by the patients them-
selves or their relatives. Its efficiency must have varied
greatly, but was generally more carefully executed in the
more severe cases. Systemic sulphonamides have been pre-
scribed more often in the past 2 years.
The grading of severity was that used in Part 11." The
cure rate in grades 3 - 5 (81'1%) was higher than that for
the mild cases of grades 1 and 2 (79'1%). This could re-
flect a greater incentive to achieve a cure in the severer
grades, but the difference is not significant. The relapse
or reinfection rate for grades 3 - 5 (30'2%) was more
significantly higher than for grades 1 and 2 (20'8%), and
could be due to the lesser resistance implied by the more
severe disease.
Associated pathologies which appeared to have reduced
the resistance to trachoma in some degree were recorded
in 156 of the 182 patients (85'7%). In 35 of these, elimi-
nation of the associated pathology helped the trachoma
treatment enormously. In 17 others, trachoma treatment
was seriously prejudiced by intractable other pathology.
In 18 patients 24 associated conditions were improved
after cure of the trachoma. These included corneal opaci-
fication in 8 cases, 4 cases with herpetic keratitis, 4 chemical
burns, 2 keratoconus cases and one each of episcleritis,
old interstitial keratitis, dacryocystitis and endothelial dys-
trophy. A postnasal drip of 20 years' duration has not
recurred for 2 years after cure of trachoma.
The 11 patients of Table I, and others not included in
the 182, improved significantly or dramatically on inten-
sive corticosteroid eyedrops. Three had previously deterio-
rated after topical corticosteroid 4 times a day, but some
months later responded well to corticosteroid eyedrops
10 - 20 times a day.' The reason for the later good re-
sponse may have been the increased dosage, or perhaps a
reduction in the infecting agent after further treatment.
Nine cases had associated pathologies which were im-
proved by topical corticosteroids, including 3 with
general allergies, 2 with marked marginal blepharitis and
solar sensitivity, and one each with episcleritis, erythema
multiforme, postoperative uveitis and keratitis, and a re-
cent chemical burn.
Only 2 patients were considered as clinically cured after
less than 3 months' treatment. In each case, elimination
of an acute aggravating factor appeared to be responsible.
One had a firmly embedded subtarsal foreign body, and
the other staphylococcal ulcerative blepharitis. Clinical
signs of bacterial infection were rare in this group, so that
the benefit from treatment appeared to be from the effect
of the drugs on the trachoma agent and from control of
associated pathologies, rather- than from elimination of
superinfection.
The above results of treatment may be compared
with results reported elsewhere. Early trials of all the
common antitrachoma drugs reported cure rates of
usually 75% - 98 %.'16 Recent controlled trials have often
reported failure or only partial success.",T.l,,.·81,l1•. '20 Bietti
et al." state that practically every case can be cured if
the therapy is continued for long enough, and this has
also been my experience. Other reported trials have rarely
continued therapy for more than 6 continuous weeks and
this could explain the disappointing results.
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Fortunately, trachoma appears to be becoming less
severe and less common in at least 18 countries as testi-
fied by 40 references.m . ,oo In my experience Natal and
Zululand can be added to this list. Part of the improve-
ment may be due to improved living standards.
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CONCLUSIONS AND SUMMARY: PARTS I - v
Trachoma was found to be very common in all racial groups
in Natal and Zululand (Part I) with severity varying from
asymptomatic to the severe classical form of the disease (part
IT). Trachomatous infection was found to be influenced by
associated pathologies in most White patients, and in some
cases treatment resulted in improvement of the associated
pathology (Part ITI). The hypersensitivity and possible toxic
aspect were discussed in Part IV.
In Part V the correlation of the variable clinical picture and
non-ocular sites of TRIC infection, largely by comparison with
the essential pathology of tuberculosis, was attempted in the
hope of providing a truer perspective of the infection than has
been allowed by classical concepts. Various factors pertaining
to treatment have been discussed and results in 182 White
private patients have been reported. For success, 3 - 6 months
of treatment, and more in refractory cases, is usually required,
but in all cases persistence has been rewarded.
My indebtedness to those institutions and persons acknow-
ledged in earlier parts is gratefully recalled. In this concluding
section I am especially mindful of the support and hospitality
provided by mission doctors and general practitioners, especi-
ally in the more remote areas of Natal, Zululand and
Tongaland.
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THE SCOPE OF FLUORESCEIN ANGIOGRAPHY*
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Fig. 1. Diagrammatic representation of camera system used with fluorescein angiography.
The passage of the dye through the retinal vessels is
then observed by the photographer, who needs to be dark-
adapted to focus the camera satisfactorily. Serial photo-
graphs are. taken at 2-second intervals, under direct ob-
servation.
Camera System'
The basic unit used was the Zeiss fundus camera which
has been adapted for f1uorescein photography by incor-
porating a high-power, rapid recycling, flash generator
(Fig. 1). This generator has power increment stages of
120, 240, 480 and 840 watt-seconds, with a timing se-
quence of 0'6-, 0'8-, 1'0-, 1'2-, 1,5- and 2-second intervals.
In order to obtain the most rapid working sequence at
0·6 seconds, the generator must be
set at the minimum output of 120
watt-seconds. The recording camera
is one which incorporates an auto-
matic film advance with a time lag
of camera release to complete
shutter openings of 20 ± 5 msec.
There is an illuminated instru-
ment panel with a frame counter,
clock' and inscription area. The data
from this panel are projected by
means of a mirror and auxiliary
lens as an 8 x 8-mm. image in the
upper left corner of each frame.
The camera lens system has also
been modified by inserting an addi-
tional objective lens which is placed
immediately in front of the camera
shutter, leaving just enough clear-
ance for a barrier filter. The objec-
tive lens gives improved results by
f- I ....Ifi=,+"(J!'OC "AI,
l",...aCITOIl fill" s.c.l2(zms)
Novotny and Alvis' first described a method of studying
the retinal circulation using intravenous fluorescein with
retinal photography.
Fluorescein angiography has added a new dimension to
the study of anatomical details and pathological changes
of the retinal microcirculation.
METHOD
The patient's pupils are dilated with Cyclomydril (cyclogyl
0·2%, phenylephrine hydrocWoride 1% and polyvinyl
pyrrolidone 3%) and a colour photograph of the fundus
is taken. An assistant then injects 5 mJ. of 10% f1uorescein
sodium into the antecubital vein.
'Date received: 6 June 1968.
